Skip to main content
SpringerLink
Log in

Should neutralizing antibodies be monitored during interferon-β treatment for multiple sclerosis?

  • Practice Point
  • Published:

From Nature Clinical Practice Neurology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Giovannoni G et al. (2002) Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 73: 465–469

    Article  CAS  Google Scholar 

  2. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47: 889–894

  3. PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56: 1628–1636

  4. Francis GS et al. (2005) Interferon β-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65: 48–55

    Article  CAS  Google Scholar 

  5. Panitch H et al. (2005) Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 239: 67–74

    Article  CAS  Google Scholar 

  6. Rice GPB et al. (1999) The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 52: 1277–1279

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Carol Lovegrove, Freelance Medical Writer.

Author information

Authors and Affiliations

  1. Division of Neurology, the Department of Pathology and the Division of Neurosciences,

    Joel Oger & Ebrima Gibbs

  2. Director of the MS Clinic and the MS Clinical trial group,

    Joel Oger & Ebrima Gibbs

  3. University of British Columbia, Vancouver, Canada

    Joel Oger & Ebrima Gibbs

Authors
  1. Joel Oger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ebrima Gibbs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel Oger.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oger, J., Gibbs, E. Should neutralizing antibodies be monitored during interferon-β treatment for multiple sclerosis?. Nat Rev Neurol 2, 76–77 (2006). https://doi.org/10.1038/ncpneuro0098

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0098

  • Springer Nature Limited

Search

Navigation